tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

ANI Pharmaceuticals Inc

ANIP
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
79.240USD
-1.190-1.48%
์ข…๊ฐ€ย 07-31 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
1.80B์‹œ๊ฐ€์ด์•ก
19.26P/E TTM
์ƒ์„ธ ์ฐจํŠธ ๋ณด๊ธฐ
TradingKey ์ฐจํŠธ
Intraday
1m
30m
1h
D
W
M
D

์˜ค๋Š˜

-1.48%

5์ผ

+2.05%

1๊ฐœ์›”

-4.59%

6๊ฐœ์›”

-0.95%

์˜ฌํ•ด ํ˜„์žฌ๊นŒ์ง€

+0.38%

1๋…„

+23.95%

ํ•ต์‹ฌ ์ˆ˜์น˜
79.650์‹œ๊ฐ€
80.380์ตœ๊ณ ๊ฐ€
205.18K๊ฑฐ๋ž˜๋Ÿ‰
19.26P/E TTM
7.42๋™์  P/E ๋น„์œจ
--๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
0.91%ํšŒ์ „์œจ
80.430์ „์ผ ์ข…๊ฐ€
78.240์ตœ์ €๊ฐ€
13.56M๋งค์ถœ์•ก
์†์‹ค์ฃผ๊ฐ€์ˆ˜์ต๋น„์œจ
3.52P/B
0.00%๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
6.79%ROA
99.50052์ฃผ ์ตœ๊ณ ๊ฐ€
0.82๊ฑฐ๋ž˜๋Ÿ‰ ๋น„์œจ
-20.15M์ˆœ์ด์ต
22.47M์ฃผ์‹
4.1138์ฃผ๋‹น์ˆœ์ด์ต
0.45๋ฒ ํƒ€
17.11%ROE
57.33052์ฃผ ์ตœ์ €๊ฐ€
2.66%๋ณ€๋™ ํญ
51.78%์ด ์ด์ต๋ฅ 
1.80B์‹œ๊ฐ€์ด์•ก
-2.77๋ณด์ƒ/์œ„ํ—˜
1.96%์œ„ํ—˜๋ฅ 

TradingKey ANI Pharmaceuticals Inc ์ฃผ์‹ ์ ์ˆ˜๎˜

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2026-07-31

์ฃผ์š” ์ธ์‚ฌ์ดํŠธ

ANI Pharmaceuticals Inc์˜ ํŽ€๋”๋ฉ˜ํ„ธ์€ ๋น„๊ต์  ๊ฑด์ „ํ•œ ์ƒํƒœ์ด๋ฉฐ, ์„ฑ์žฅ ์ž ์žฌ๋ ฅ์€ ๋†’์Šต๋‹ˆ๋‹ค.๊ธฐ์—…์˜ ๋ฐธ๋ฅ˜์—์ด์…˜์€ ์ ์ •ํ•˜๊ฒŒ ํ‰๊ฐ€๋œ ๊ฒƒ์œผ๋กœ ๊ฐ„์ฃผ๋˜๋ฉฐ, ์ œ์•ฝ ์‚ฐ์—…์—์„œ 155๊ฐœ ์ค‘ 10์œ„ ๋žญํ‚น.๊ธฐ๊ด€ ๋ณด์œ  ๋น„์œจ์€ ๋งค์šฐ ๋†’์€.์ง€๋‚œ ํ•œ ๋‹ฌ ๋™์•ˆ ์—ฌ๋Ÿฌ ์• ๋„๋ฆฌ์ŠคํŠธ๊ฐ€ ํ•ด๋‹น ๊ธฐ์—…์„ ๋งค์ˆ˜(์œผ)๋กœ ํ‰๊ฐ€ํ–ˆ์œผ๋ฉฐ, ์ตœ๊ณ  ๋ชฉํ‘œ ๊ฐ€๊ฒฉ์€ 109.29์ž…๋‹ˆ๋‹ค.์ค‘๊ธฐ์ ์œผ๋กœ ์ฃผ๊ฐ€๋Š” ์•ˆ์ •์ ์ธ ์ƒํƒœ๋ฅผ ์œ ์ง€ํ•  ๊ฒƒ์œผ๋กœ ์˜ˆ์ƒ๋ฉ๋‹ˆ๋‹ค.์ง€๋‚œ ํ•œ ๋‹ฌ๊ฐ„ ์ฃผ์‹ ์‹œ์žฅ์—์„œ ๋ถ€์ง„ํ•œ ์„ฑ๊ณผ๋ฅผ ๊ฑฐ๋‘์—ˆ์ง€๋งŒ, ๊ธฐ์—…์˜ ํŽ€๋”๋ฉ˜ํ„ธ์€ ํƒ„ํƒ„ํ•ฉ๋‹ˆ๋‹ค.์ฃผ๊ฐ€๋Š” ์ง€์ง€์„ ๊ณผ ์ €ํ•ญ์„  ์‚ฌ์ด์—์„œ ํšก๋ณดํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ๋ฒ”์œ„ ๋งค๋งค ๊ธฐ๋ฐ˜์˜ ์Šค์œ™ ํŠธ๋ ˆ์ด๋”ฉ์— ์ ํ•ฉํ•œ ์ƒํ™ฉ์ž…๋‹ˆ๋‹ค.

ANI Pharmaceuticals Inc ์ ์ˆ˜๎˜ฐ๎˜ฐ

๊ด€๋ จ ์ •๋ณด

์‚ฐ์—… ์ˆœ์œ„
10 / 155
์ „์ฒด ์ˆœ์œ„
38 / 4281
์‚ฐ์—…
์ œ์•ฝ

์ €ํ•ญ์„  & ์ง€์ง€์„ 

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

๋ ˆ์ด๋” ์ฐจํŠธ

ํ˜„์žฌ ๊ฐ€๊ฒฉ
๊ณผ๊ฑฐ

๋ฏธ๋””์–ด ๋ณด๋„

์ตœ๊ทผ 24 ์‹œ๊ฐ„
๋ณด๋„ ์ˆ˜์ค€

๋งค์šฐ ๋‚ฎ์€
๋งค์šฐ ๋†’์€
๊ธ์ •+

ANI Pharmaceuticals Inc ์ฃผ์š” ๋‚ด์šฉ

๊ฐ•์ ์œ„ํ—˜ ์š”์†Œ
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
๋†’์€ ์„ฑ์žฅ
ํšŒ์‚ฌ์˜ ๋งค์ถœ์€ ์ง€๋‚œ 3๋…„๊ฐ„ ๊พธ์ค€ํžˆ ์„ฑ์žฅํ•ด์™”์œผ๋ฉฐ, ์—ฐํ‰๊ท  81.46%์˜ ์ฆ๊ฐ€์œจ์„ ๊ธฐ๋กํ–ˆ์Šต๋‹ˆ๋‹ค.
๊ณ ์ˆ˜์ต ์„ฑ์žฅ
ํšŒ์‚ฌ์˜ ์ˆœ์ด์ต์€ ์—…๊ณ„ ์„ ๋‘๋ฅผ ๋‹ฌ๋ฆฌ๊ณ  ์žˆ์œผ๋ฉฐ, ์ตœ๊ทผ ์—ฐ๊ฐ„ ์ˆœ์ด์ต์€ ๋ฏธํ™” 883.37M์— ๋‹ฌํ•ฉ๋‹ˆ๋‹ค.
์ด์ต ์ „ํ™˜
ํšŒ์‚ฌ์˜ ์‹ค์ ์ด ํ‘์ž๋กœ ์ „ํ™˜๋˜์–ด, ์ตœ๊ทผ ์—ฐ๊ฐ„ ์ˆœ์ด์ต์€ ๋ฏธํ™” ๋‹ฌ๋Ÿฌ์— ๋‹ฌํ•ฉ๋‹ˆ๋‹ค.
๊ณต์ •ํ•œ ๊ฐ€์น˜
ํšŒ์‚ฌ์˜ ์ตœ์‹  PE์€ 19.26๋กœ, ์ตœ๊ทผ 3๋…„ ๊ธฐ์ค€ ์ค‘๊ฐ„ ๋ฐฑ๋ถ„์œ„ ๋ฒ”์œ„์— ์†ํ•ฉ๋‹ˆ๋‹ค.
๊ธฐ๊ด€ ๋งค์ˆ˜
์ตœ์‹  ๊ธฐ๊ด€ ๋ณด์œ  ์ฃผ์‹ ์ˆ˜๋Š” 23.15M์ฃผ์ด๋ฉฐ, ์ „ ๋ถ„๊ธฐ ๋Œ€๋น„ 0.25% ์ฆ๊ฐ€ํ–ˆ์Šต๋‹ˆ๋‹ค.
์กด ํ—ˆ์Šค๋งŒ๊ฐ€ ๋ณด์œ 
์Šคํƒ€ ํˆฌ์ž์ž ์กด ํ—ˆ์Šค๋งŒ์ด(๊ฐ€) ์ด ์ฃผ์‹ 49.41K์ฃผ๋ฅผ ๋ณด์œ ํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค.

๋ถ„์„๊ฐ€ ๋ชฉํ‘œ๊ฐ€

8 ๋ช…์˜ ๋ถ„์„๊ฐ€๋ฅผ ๊ธฐ์ค€์œผ๋กœ
๋งค์ˆ˜
ํ˜„์žฌ ๋“ฑ๊ธ‰
109.286
๋ชฉํ‘œ ๊ฐ€๊ฒฉ
+37.92%
์ƒ์Šน ์—ฌ๋ ฅ

ANI Pharmaceuticals Inc ๋‰ด์Šค

๋” ๋งŽ์€ ๋‰ด์Šค๊ฐ€ ๊ณง ์—…๋ฐ์ดํŠธ๋ฉ๋‹ˆ๋‹ค. ๊ณ„์† ์ง€์ผœ๋ด ์ฃผ์„ธ์š”โ€ฆ

์˜ˆ์ƒ๎˜

์• ๋„๋ฆฌ์ŠคํŠธ ํ‰๊ฐ€

8 ๋ช…์˜ ๋ถ„์„๊ฐ€๋ฅผ ๊ธฐ์ค€์œผ๋กœ
๋งค์ˆ˜
ํ˜„์žฌ ๋“ฑ๊ธ‰
109.286
๋ชฉํ‘œ ๊ฐ€๊ฒฉ
+37.92%
์ƒ์Šน ์—ฌ๋ ฅ
๊ฐ•๋ ฅ ๋งค์ˆ˜
๋งค์ˆ˜
์œ ์ง€
๋งค๋„
๊ฐ•๋ ฅ ๋งค๋„

๋™์ข…์—…๊ณ„ ๋น„๊ต

160
์ด๊ณ„
6
์ค‘๊ฐ„
9
ํ‰๊ท 
ํšŒ์‚ฌ ์ด๋ฆ„
ํ‰๊ฐ€
๋ถ„์„๊ฐ€
ANI Pharmaceuticals Inc
ANIP
8
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32

์ง€ํ‘œ๎˜

์ง€ํ‘œ
๋งค๋„(4)
์ค‘๋ฆฝ(3)
๋งค์ˆ˜(0)
์ง€ํ‘œ
๊ฐ€์น˜
๋ฐฉํ–ฅ
MACD(12,26,9)
-0.000
๋งค๋„
RSI(14)
45.744
์ค‘๋ฆฝ
STOCH(KDJ)(9,3,3)
60.257
์ค‘๋ฆฝ
ATR(14)
2.299
๊ณ ๋ณ€๋™์„ฑ
CCI(14)
-17.640
์ค‘๋ฆฝ
Williams %R
56.990
๋งค๋„
TRIX(12,20)
-0.172
๋งค๋„
StochRSI(14)
29.901
๋งค๋„
์ด๋™ ํ‰๊ท 
๋งค๋„(5)
์ค‘๋ฆฝ(0)
๋งค์ˆ˜(1)
์ง€ํ‘œ
๊ฐ€์น˜
๋ฐฉํ–ฅ
MA5
80.172
๋งค๋„
MA10
79.152
๋งค์ˆ˜
MA20
80.837
๋งค๋„
MA50
81.115
๋งค๋„
MA100
79.439
๋งค๋„
MA200
81.244
๋งค๋„

์žฌ๋ฌด ์ง€ํ‘œ๎˜

EPS

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ด ์ˆ˜์ต

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

ANI Pharmaceuticals Inc ์ •๋ณด๎˜

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
์ข…๋ชฉ ์ฝ”๋“œ ANIP
ํšŒ์‚ฌANI Pharmaceuticals Inc
CEOLalwani (Nikhil Suresh)
์›น์‚ฌ์ดํŠธhttps://www.anipharmaceuticals.com/

์ฃผ์ฃผ๎˜

์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
BlackRock Institutional Trust Company, N.A.
10.76%
Meridian Venture Partners
4.46%
Vanguard Capital Management, LLC
3.62%
State Street Investment Management (US)
3.20%
Millennium Management LLC
2.37%
๊ธฐํƒ€
75.58%

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

ANI Pharmaceuticals Inc(ANIP)์˜ ํ˜„์žฌ ๊ฐ€๊ฒฉ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
ANI Pharmaceuticals Inc(ANIP)์˜ ํ˜„์žฌ ์ฃผ๊ฐ€๋Š” 79.24์ž…๋‹ˆ๋‹ค.

ANI Pharmaceuticals Inc์˜ ์ข…๋ชฉ ๊ธฐํ˜ธ(Symbol)๋Š” ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
ANI Pharmaceuticals Inc์˜ ์ข…๋ชฉ ์ฝ”๋“œ๋Š” ANIP์ž…๋‹ˆ๋‹ค.

ANI Pharmaceuticals Inc์˜ 52์ฃผ ์ตœ๊ณ ๊ฐ€๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
ANI Pharmaceuticals Inc์˜ 52์ฃผ ์ตœ๊ณ ๊ฐ€๋Š” 99.50์ž…๋‹ˆ๋‹ค.

ANI Pharmaceuticals Inc์˜ 52์ฃผ ์ตœ์ €๊ฐ€๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
ANI Pharmaceuticals Inc์˜ 52์ฃผ ์ตœ์ €๊ฐ€๋Š” 57.33์ž…๋‹ˆ๋‹ค.

ANI Pharmaceuticals Inc์˜ ์‹œ๊ฐ€์ด์•ก์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
ANI Pharmaceuticals Inc์˜ ์‹œ๊ฐ€์ด์•ก์€ 1.78B์ž…๋‹ˆ๋‹ค.

ANI Pharmaceuticals Inc(ANIP)์˜ ํ˜„์žฌ ํˆฌ์ž ๋“ฑ๊ธ‰์€ ๋งค์ˆ˜, ๋ณด์œ , ๋งค๋„ ์ค‘ ์–ด๋–ค๊ฐ€์š”?

๎™Œ
์• ๋„๋ฆฌ์ŠคํŠธ๋“ค์— ๋”ฐ๋ฅด๋ฉด, ANI Pharmaceuticals Inc(ANIP)๋Š” ์ „๋ฐ˜์ ์ธ ํ‰๊ฐ€์—์„œ ๊ตฌ์ž…ํ•˜๋‹ค ๋“ฑ๊ธ‰์„ ๋ฐ›๊ณ  ์žˆ์œผ๋ฉฐ, ๋ชฉํ‘œ ์ฃผ๊ฐ€๋Š” 109.29์ž…๋‹ˆ๋‹ค.

ANI Pharmaceuticals Inc(ANIP)์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS TTM)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
ANI Pharmaceuticals Inc(ANIP)์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS TTM)์€ 3.50์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ